The world’s largest biotechnology company pleaded guilty in federal court today for improper marketing practices involving its anemia drug Aranesp, and says it will pay $762 million in a combination of civil settlements and criminal fines. It won’t lose out on any federal business or contracts, however, which would’ve been a veritable death knell for the company. [More]
